Klus Pharma

Focus: Klus Pharma is a public-stage oncology-focused pharmaceutical company headquartered in Princeton, NJ, developing generics, biologics, and small molecules across multiple cancer indications.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Klus Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Klus Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

A166

HER2-positive Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT03602079Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Phase 1/2

Help build intelligence for Klus Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Oncology-focused pipeline with 4 active programs spanning HER2+ breast cancer, NSCLC, and ovarian cancer, offering exposure to high-impact therapeutic areas
Public company status provides equity liquidity and potential upside from pipeline advancement through Phase 2 trials
Diverse modality expertise across generics, biologics, and small molecules enables broad skill-building across drug development platforms

Watch Out For

Zero active job openings signals either hiring freeze, minimal growth mode, or organizational restructuring, creating limited entry points
No Phase 3 programs in pipeline and only early-stage Phase 1/2 trials indicate 5+ years minimum to potential first NDA, creating extended pre-revenue uncertainty
Absence of disclosed financials, R&D spend, cash position, and employee count raises transparency concerns about company stability and resource availability

Generated by Claude from Klus Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SKB264

Epithelial Ovarian Cancer

Phase 1/2

Clinical Trials (1)

NCT04152499Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Phase 1/2

SKB264

Non-small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT05816252A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

Phase 2

SKB264

Solid Tumor

Phase 2

Clinical Trials (1)

NCT05642780SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Phase 2